Brief: Quoin Pharmaceuticals Announces Additional Positive Interim Data From Ongoing Open-Label Netherton Syndrome Clinical Study
06/01/2025 14:51
Jan 6 (Reuters) - Quoin Pharmaceuticals Ltd 2EBy.BE :
* QUOIN PHARMACEUTICALS ANNOUNCES ADDITIONAL POSITIVE
INTERIM DATA
FROM ONGOING OPEN-LABEL NETHERTON SYNDROME CLINICAL STUDY
* QUOIN PHARMACEUTICALS LTD - NO SAFETY CONCERNS REPORTED IN
QRX003 STUDY
Source text: urn:newsml:reuters.com:*:nGNX1BtRrt
Further company coverage: 2EBy.BE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Quoin Pharmaceuticals
See all newsQuoin Pharmaceuticals Ltd reports results for the quarter ended June 30 - Earnings Summary
Quoin Pharmaceuticals Ltd expected to post a loss of $1.61 a share - Earnings Preview
Quoin Pharmaceuticals Ltd expected to post a loss of $1.61 a share - Earnings Preview
NASDAQ RESUMED AT 10:15 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:06 AM